Context Therapeutics (NASDAQ:CNTX) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Key Points

• Context Therapeutics reported Q EPS of ($0.09), beating the consensus estimate of ($0.12) by $0.03.
• Shares fell about 1.2% to $2.41 on Wednesday with volume of 506,317 (avg ~977,034); the company has a market cap of ~$221.4M and a 12‑month range of $0.49–$3.62.
• Several analysts raised targets (Piper Sandler to $7, D. Boral to $9, Guggenheim to $5) while one downgraded to a sell, leaving a consensus rating of "Moderate Buy" and an average price target of $6.60.

Context Therapeutics (NASDAQ:CNTX - Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.03, FiscalAI reports.

Context Therapeutics Stock Down 1.2%

Shares of CNTX traded down $0.03 during trading on Wednesday, reaching $2.41. The company's stock had a trading volume of 506,317 shares, compared to its average volume of 977,034. The company has a fifty day moving average of $2.63 and a two-hundred day moving average of $1.90. Context Therapeutics has a twelve month low of $0.49 and a twelve month high of $3.62. The company has a market cap of $221.43 million, a price-to-earnings ratio of -6.34 and a beta of 1.57.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. Piper Sandler boosted their price target on Context Therapeutics from $4.00 to $7.00 and gave the stock an "overweight" rating in a research report on Tuesday, March 24th. D. Boral Capital reissued a "buy" rating and set a $9.00 price target on shares of Context Therapeutics in a research report on Tuesday, March 24th. Guggenheim reissued a "buy" rating and set a $5.00 price target on shares of Context Therapeutics in a research report on Tuesday, March 24th. Wall Street Zen lowered Context Therapeutics from a "hold" rating to a "sell" rating in a research report on Sunday, March 29th. Finally, Lifesci Capital raised Context Therapeutics to a "strong-buy" rating in a research report on Monday, February 23rd. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $6.60.

Hedge Funds Weigh In On Context Therapeutics

A number of institutional investors have recently made changes to their positions in the business. Virtu Financial LLC acquired a new position in shares of Context Therapeutics in the 4th quarter valued at approximately $43,000. XTX Topco Ltd raised its position in shares of Context Therapeutics by 858.8% in the 4th quarter. XTX Topco Ltd now owns 101,605 shares of the company's stock valued at $149,000 after purchasing an additional 91,008 shares in the last quarter. Quadrature Capital Ltd acquired a new position in shares of Context Therapeutics in the 4th quarter valued at approximately $68,000. Millennium Management LLC acquired a new position in shares of Context Therapeutics in the 4th quarter valued at approximately $3,824,000. Finally, Marshall Wace LLP raised its position in shares of Context Therapeutics by 7,153.7% in the 4th quarter. Marshall Wace LLP now owns 2,593,198 shares of the company's stock valued at $3,812,000 after purchasing an additional 2,557,448 shares in the last quarter. 14.03% of the stock is owned by institutional investors and hedge funds.

Context Therapeutics Company Profile

Context Therapeutics NASDAQ: CNTX is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company's research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.